Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Athersys Inc (ATHX)

Athersys Inc (ATHX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Athersys Inc 3201 CARNEGIE AVENUE CLEVELAND OH 44115 USA

www.athersys.com P: 216-431-9900

Description:

Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an `off the shelf` allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD).

Key Statistics

Overview:

Market Capitalization, $K 833
Enterprise Value, $K -8,207
Shares Outstanding, K 61,719
Annual Sales, $ 5,330 K
Annual Net Income, $ -72,530 K
Last Quarter Sales, $ 50 K
Last Quarter Net Income, $ -12,920 K
EBIT, $ -50,050 K
EBITDA, $ -48,630 K
60-Month Beta -0.90
% of Insider Shareholders 0.03%
% of Institutional Shareholders 19.35%
Float, K 61,700
% Float 99.97%
Short Volume Ratio 0.22

Growth:

1-Year Return -98.59%
3-Year Return -99.97%
5-Year Return -99.96%
5-Year Revenue Growth 43.67%
5-Year Earnings Growth 16.28%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 11/16/23
Latest Earnings Date 11/20/23
Earnings Per Share ttm -3.03
EPS Growth vs. Prev Qtr 75.81%
EPS Growth vs. Prev Year 86.96%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 08/29/22

ATHX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -223.03%
Profit Margin % -1,360.79%
Debt/Equity 0.00
Price/Sales 11.61
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.71
Interest Coverage -3.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar